busulfan has been researched along with Cytomegalovirus Infections in 23 studies
Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 9.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "We describe the case of a 16-month-old girl with neuroblastoma and chronic lymphocytopenia due to chemotherapy and treosulfan-containing megatherapy who developed cytomegalovirus retinitis and neuritis." | 7.81 | Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant. ( Bilska, K; Prost, M; Raciborska, A; Rodriguez-Galindo, C; Rychlowska-Pruszynska, M; Ussowicz, M, 2015) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 7.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)." | 5.07 | A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994) |
| "We describe the case of a 16-month-old girl with neuroblastoma and chronic lymphocytopenia due to chemotherapy and treosulfan-containing megatherapy who developed cytomegalovirus retinitis and neuritis." | 3.81 | Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant. ( Bilska, K; Prost, M; Raciborska, A; Rodriguez-Galindo, C; Rychlowska-Pruszynska, M; Ussowicz, M, 2015) |
| " Following allogeneic bone marrow transplantation, he developed cytomegalovirus retinitis, which was treated successfully with trisodium phosphonoformate (foscarnet)." | 3.67 | Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation. ( Arthur, C; Ganly, PS; Goldman, JM; Schulenburg, WE, 1988) |
| "In order to assess the performance of Bayesian individualization of busulfan (BU) dosage regimens, veno-occlusive disease (VOD) rate was monitored for paediatric patients undergoing allogeneic bone marrow transplantation (BMT)." | 1.35 | Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics. ( Brice, K; Claire, G; Gilles, A; Nathalie, B; Valerie, B; Valerie, M; Yves, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Zhao, J | 1 |
| Fei, X | 1 |
| Yin, Y | 1 |
| Cheng, H | 1 |
| Zhang, W | 1 |
| Gu, J | 1 |
| Yang, F | 1 |
| Yang, Y | 1 |
| Xue, S | 1 |
| Tian, Z | 1 |
| He, J | 1 |
| Zhang, S | 1 |
| Wang, X | 1 |
| Taimur, S | 1 |
| Askar, M | 1 |
| Sobecks, R | 1 |
| Rybicki, L | 1 |
| Warshawsky, I | 1 |
| Mossad, S | 1 |
| Uhm, J | 1 |
| Hamad, N | 1 |
| Michelis, FV | 1 |
| Shanavas, M | 1 |
| Kuruvilla, J | 1 |
| Gupta, V | 1 |
| Lipton, JH | 1 |
| Messner, HA | 1 |
| Seftel, M | 1 |
| Kim, DD | 1 |
| Raciborska, A | 1 |
| Ussowicz, M | 1 |
| Prost, M | 1 |
| Bilska, K | 1 |
| Rodriguez-Galindo, C | 1 |
| Rychlowska-Pruszynska, M | 1 |
| Shigematsu, A | 1 |
| Yasumoto, A | 1 |
| Yamamoto, S | 1 |
| Sugita, J | 1 |
| Kondo, T | 1 |
| Onozawa, M | 1 |
| Kahata, K | 1 |
| Endo, T | 1 |
| Ota, S | 1 |
| Sato, N | 1 |
| Takahata, M | 1 |
| Okada, K | 1 |
| Tanaka, J | 1 |
| Hashino, S | 1 |
| Nishio, M | 1 |
| Koike, T | 1 |
| Asaka, M | 1 |
| Imamura, M | 1 |
| Barker, CC | 1 |
| Butzner, JD | 1 |
| Anderson, RA | 1 |
| Brant, R | 1 |
| Sauve, RS | 1 |
| Maschan, AA | 1 |
| Trakhtman, PE | 1 |
| Balashov, DN | 1 |
| Shipicina, IP | 1 |
| Skorobogatova, EV | 1 |
| Skvortsova, YV | 1 |
| Dyshlevaja, ZM | 1 |
| Samochatova, EV | 1 |
| Rumiantsev, AG | 1 |
| Rao, PS | 1 |
| Kean, LS | 1 |
| Adams, AB | 1 |
| Strobert, E | 1 |
| Hendrix, R | 1 |
| Gangappa, S | 1 |
| Jones, TR | 1 |
| Shirasugi, N | 1 |
| Rigby, MR | 1 |
| Hamby, K | 1 |
| Jiang, J | 1 |
| Bello, H | 1 |
| Anderson, D | 1 |
| Cardona, K | 1 |
| Durham, MM | 1 |
| Pearson, TC | 1 |
| Larsen, CP | 1 |
| Chae, YS | 1 |
| Sohn, SK | 1 |
| Kim, JG | 1 |
| Cho, YY | 1 |
| Moon, JH | 1 |
| Shin, HJ | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Yang, DH | 1 |
| Lee, JJ | 1 |
| Kim, YK | 1 |
| Kim, HJ | 1 |
| Brice, K | 1 |
| Valerie, B | 1 |
| Claire, G | 1 |
| Valerie, M | 1 |
| Yves, B | 1 |
| Gilles, A | 1 |
| Nathalie, B | 1 |
| Beschorner, WE | 1 |
| Pino, J | 1 |
| Boitnott, JK | 1 |
| Tutschka, PJ | 2 |
| Santos, GW | 1 |
| Canioni, D | 1 |
| Vassal, G | 1 |
| Donadieu, J | 1 |
| Hubert, PH | 1 |
| Brousse, N | 1 |
| Quigley, PM | 1 |
| Yeager, AM | 1 |
| Loughlin, GM | 1 |
| Ringdén, O | 1 |
| Ruutu, T | 1 |
| Remberger, M | 1 |
| Nikoskelainen, J | 1 |
| Volin, L | 1 |
| Vindeløv, L | 1 |
| Parkkali, T | 1 |
| Lenhoff, S | 1 |
| Sallerfors, B | 1 |
| Ljungman, P | 1 |
| Perez-Ceballos, E | 1 |
| Vallejo, C | 1 |
| Cano, H | 1 |
| Ayala, F | 1 |
| Martínez, F | 1 |
| Moraleda, J | 1 |
| Vicente, V | 1 |
| Hebart, H | 1 |
| Wuchter, P | 1 |
| Loeffler, J | 1 |
| Gscheidle, B | 1 |
| Hamprecht, K | 1 |
| Sinzger, C | 1 |
| Jahn, G | 1 |
| Dietz, K | 1 |
| Kanz, L | 1 |
| Einsele, H | 1 |
| Nakai, K | 1 |
| Kanda, Y | 1 |
| Mineishi, S | 1 |
| Saito, T | 1 |
| Ohnishi, M | 1 |
| Niiya, H | 1 |
| Chizuka, A | 1 |
| Takeuchi, T | 1 |
| Matsubara, H | 1 |
| Kami, M | 1 |
| Makimoto, A | 1 |
| Tanosaki, R | 1 |
| Kunitoh, H | 1 |
| Tobinai, K | 1 |
| Takaue, Y | 1 |
| Baronciani, D | 1 |
| Polchi, P | 2 |
| Lucarelli, G | 2 |
| Filocamo, M | 1 |
| Galimberti, M | 1 |
| Angelucci, E | 1 |
| Durazzi, SM | 1 |
| Giardini, C | 1 |
| Bartolucci, M | 1 |
| Andreani, M | 1 |
| Centis, F | 1 |
| Rossi, MC | 1 |
| La Nasa, G | 1 |
| De Biagi, M | 1 |
| Ganly, PS | 1 |
| Arthur, C | 1 |
| Goldman, JM | 1 |
| Schulenburg, WE | 1 |
| Green, GI | 1 |
| Levin, RL | 1 |
| Pierce, LE | 1 |
| Witorsch, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome[NCT03858530] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-05-01 | Active, not recruiting | ||
| Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome[NCT03865589] | 250 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | |||
| Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients[NCT03963999] | Phase 4 | 0 participants (Actual) | Interventional | 2020-04-01 | Withdrawn (stopped due to We did not receive grant funding. We will reapply in June of 2020) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for busulfan and Cytomegalovirus Infections
| Article | Year |
|---|---|
A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Child; Child, Preschool; C | 1994 |
22 other studies available for busulfan and Cytomegalovirus Infections
| Article | Year |
|---|---|
A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Cystitis; Cytarabine; Cytomegalovirus Infections; Dru | 2018 |
Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Cohort Studies; Cyclophosphamide; Cyclosporine; Cytome | 2014 |
The risk of polyomavirus BK-associated hemorrhagic cystitis after allogeneic hematopoietic SCT is associated with myeloablative conditioning, CMV viremia and severe acute GVHD.
Topics: Adolescent; Adult; Aged; BK Virus; Busulfan; Cystitis; Cytomegalovirus Infections; Female; Graft vs | 2014 |
Effective treatment of cytomegalovirus retinitis and neuritis with retrobulbar ganciclovir after treosulfan-based autologous bone marrow transplant.
Topics: Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cytomega | 2015 |
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antigens, Viral; Bone Marrow Transplantation; Busulf | 2009 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients.
Topics: Busulfan; Child; Child, Preschool; Cohort Studies; Cytomegalovirus Infections; Female; Hematologic D | 2003 |
Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
Topics: Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegaloviru | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineop | 2005 |
Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression.
Topics: Animals; Bone Marrow Transplantation; Busulfan; Chimerism; Cytomegalovirus Infections; Hematopoietic | 2007 |
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infectio | 2007 |
Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Topics: Adolescent; Bayes Theorem; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegal | 2008 |
Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.
Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Carmustine; Cytomegalovirus Infections; Gra | 1980 |
Toxicity induced by chemotherapy mimicking cytomegalovirus gastritis.
Topics: Antineoplastic Agents; Busulfan; Cytomegalovirus Infections; Diagnosis, Differential; Fatal Outcome; | 1995 |
The effects of bone marrow transplantation on pulmonary function in children.
Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalov | 1994 |
Fatal upper and lower gastrointestinal cytomegalovirus disease following autologous peripheral blood stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cytomegalovirus Infections; Fatal Outcome; | 2001 |
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cells, Cultured; Cytomegalovirus; Cytomega | 2001 |
Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin.
Topics: Adolescent; Adult; Aged; Antigens, Viral; Antilymphocyte Serum; Busulfan; Cladribine; Cohort Studies | 2002 |
CMV infections in thalassemia patients after BMT.
Topics: Adolescent; Blood Transfusion; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclo | 1989 |
Immunologic recovery in thalassemic marrow graft recipients following high-dose busulfan and cyclophosphamide.
Topics: Antigens, Differentiation, T-Lymphocyte; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cy | 1988 |
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Topics: Adult; Antiviral Agents; Bone Marrow Transplantation; Busulfan; Cataract; Cytomegalovirus Infections | 1988 |
Diminishing morbidity and mortality of bone marrow transplantation.
Topics: Administration, Oral; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophospha | 1986 |
Busulfan lung complicated by pneumocystis carinii and cytomegalovirus infection.
Topics: Busulfan; Cytarabine; Cytomegalovirus Infections; Female; Humans; Leukemia, Myeloid; Lung; Middle Ag | 1974 |